氯吡格雷在冠心病中的应用

被引：20

作者：

李秀梅 ^{[1
,2
]}

胡大一 ^{[1
]}

机构：

[1] 同济大学医学院心肺血管中心

[2] 上海市第十人民医院心内科

来源：

中国临床药理学杂志 | 2010年 / 26卷 / 01期

关键词：

氯吡格雷; 冠状动脉疾病; 噻氯匹定; 血小板聚集;

D O I：

10.13699/j.cnki.1001-6821.2010.01.005

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

抗血小板在冠心病治疗中占重要地位,抗血小板药物氯吡格雷的应用,使冠心病患者大大获益;然而使用过程中,逐渐暴露出许多问题,如仍有部分患者再发血栓事件。为此本文从循证医学到临床遇到的问题及对策,就氯吡格雷在临床中应用作了较全面综述。

引用

页码：75 / 78

页数：4

共 13 条

[1]

High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients—A Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) analysis[J] . Amir Lotfi,Marc J. Schweiger,Gregory R. Giugliano,Sabina A. Murphy,Christopher P. Cannon.American Heart Journal . 2008 (5)

[2] Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel [J].

Payne, Christopher D. ;

Li, Ying Grace ;

Small, David S. ;

Ernest, C. Steven, II ;

Farid, Nagy A. ;

Jakubowski, Joseph A. ;

Brandt, John T. ;

Salazar, Daniel E. ;

Winters, Kenneth J. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (05) :555-562

[3]

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation[J] . John T. Brandt,Christopher D. Payne,Stephen D. Wiviott,Govinda Weerakkody,Nagy A. Farid,David S. Small,Joseph A. Jakubowski,Hideo Naganuma,Kenneth J. Winters.American Heart Journal . 2007 (1)

[4]

ADP Receptor Antagonism[J] . Dominick Angiolillo.American Journal of Cardiovascular Drugs . 2007 (6)

[5]

Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study[J] . Dominick J. Angiolillo,Steven B. Shoemaker,Bhaloo Desai,Hang Yuan,Ronald K. Charlton,Esther Bernardo,Martin M. Zenni,Luis A. Guzman,Theodore A. Bass,Marco A. Costa.Circulation . 2007 (6)

[6]

Initial experience with an intravenous P2Y 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial[J] . Adam B. Greenbaum,Cindy L. Grines,John A. Bittl,Richard C. Becker,Dean J. Kereiakes,Ian C. Gilchrist,Jane Clegg,Jill E. Stankowski,Donna R. Grogan,Robert A. Harrington,Hakan Emanuelsson,W. Douglas Weaver.American Heart Journal . 2006 (3)

[7]

Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting[J] . Thomas Cuisset,Corinne Frere,Jacques Quilici,Pierre-Emmanuel Morange,Lyassine Nait-Saidi,Joseph Carvajal,Agnès Lehmann,Marc Lambert,Jean-Louis Bonnet,Marie-Christine Alessi.Journal of the American College of Cardiology . 2006 (7)

[8]

A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes[J] . Gilles Montalescot,Georges Sideris,Catherine Meuleman,Claire Bal-dit-Sollier,Nicolas Lellouche,Ph. Gabriel Steg,Michel Slama,Olivier Milleron,Jean-Philippe Collet,Patrick Henry,Farzin Beygui,Ludovic Drouet.Journal of the American College of Cardiology . 2006 (5)

[9]

Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial[J] . Circulation . 2005 (19)

[10] The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting [J].

Gurbel, PA ;

Bliden, KP ;

Hayes, KM ;

Yoho, JA ;

Herzog, WR ;

Tantry, US .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (09) :1392-1396

← 1 2 →